Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
PaperCitations, authors & open-access status
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1,585 citations, 2015 year and closed oa status.
1,585
Citations
2015
Year
closed
OA Status